Minerva Neurosciences Inc. (NASDAQ:NERV) rose 3.3% on Thursday . The stock traded as high as $13.52 and last traded at $13.10, with a volume of 495,839 shares. The stock had previously closed at $12.68.

NERV has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Tuesday, August 9th. Jefferies Group reaffirmed a “buy” rating and set a $17.00 price objective on shares of Minerva Neurosciences in a research report on Wednesday, June 8th. Finally, JMP Securities upped their price objective on shares of Minerva Neurosciences from $10.00 to $17.00 in a research report on Thursday, May 26th.

The company’s market capitalization is $464.65 million. The company has a 50-day moving average price of $11.02 and a 200-day moving average price of $7.91.

Minerva Neurosciences (NASDAQ:NERV) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.12. During the same period in the previous year, the business earned ($0.27) EPS. Equities analysts forecast that Minerva Neurosciences Inc. will post ($0.90) EPS for the current fiscal year.

In other news, major shareholder Venture Associates L. Index III sold 1,000,000 shares of the firm’s stock in a transaction on Wednesday, August 10th. The stock was sold at an average price of $10.00, for a total transaction of $10,000,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David Kupfer bought 55,635 shares of the firm’s stock in a transaction dated Tuesday, June 21st. The shares were acquired at an average cost of $10.84 per share, with a total value of $603,083.40. Following the completion of the transaction, the director now owns 209,188 shares in the company, valued at $2,267,597.92. The disclosure for this purchase can be found here.

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.